The Japan Intellectual Property High Court reversed the Tokyo District Court and held that a generic narlfrafen hydrochloride (nalfurafine) anti-itch product infringes Toray’s term-extended pharmaceutical use patent on Remitch, awarding the patentee approximately ¥21.7 billion (~US$140 million) in damages. The decision expansively defines the scope of extended Japanese pharmaceutical patents — covering generics with substantively identical active ingredient, dosage, usage, and indication, not merely formally identical products.